Health Technology
Santen Pharmaceutical Co., Ltd.
In the news
- Japan's midsize drugmakers find niche in richer Southeast Asians Aug 25, 2019
- Japanese drugmaker Santen forays into India Aug 8, 2019
- Premium eyedrops sales boom with so many people staring at screens Mar 20, 2018
- Tourists to Japan now spending more on the cheap Aug 29, 2017
- Japan's Santen sets sights on world with 15-minute glaucoma treatment Mar 18, 2017 See more articles on Santen Pharmaceutical Co., Ltd.
Business Summary
Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the Pharmaceuticals and Other segments. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Other segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 234,026M | 2,110.34M |
| Gross Profit | 134,165M | 1,209.84M |
| Operating income | 41,242M | 371.90M |
| Income before tax | 43,117M | 388.81M |
| Net income | 31,953M | 288.13M |
| EBITDA | 52,211M | 470.81M |
| Diluted EPS | 78.43 | 0.70 |
| Dividends Per Share | 26 | 0.23 |
| Total Assets | 391,186M | 3,534.22M |
| Total liabilities | 98,614M | 890.94M |
| Total equity | 290,900M | 2,628.17M |
| Operating cash flow | 32,894M | 296.62M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 161,831M | 195,291M | 199,096M | 224,942M | 234,026M |
| Gross Profit | 100,660M | 115,233M | 115,763M | 129,618M | 134,165M |
| Operating income | 34,995M | 36,502M | 33,301M | 38,637M | 41,242M |
| Income before tax | 35,863M | 79,470M | 30,055M | 39,261M | 43,117M |
| Net income | 24,032M | 53,373M | 21,717M | 35,247M | 31,953M |
| EBITDA | 41,953M | 45,840M | 43,183M | 49,533M | 52,211M |
| Diluted EPS | 57.93 | 128.41 | 52.76 | 86.42 | 78.43 |
| Dividends Per Share | 22 | 25 | 26 | 26 | 26 |
| Total Assets | 304,200M | 355,399M | 358,906M | 388,463M | 391,186M |
| Total liabilities | 92,421M | 95,390M | 102,977M | 100,904M | 98,614M |
| Total equity | 211,779M | 260,009M | 255,110M | 285,823M | 290,900M |
| Operating cash flow | 25,386M | 22,525M | 10,843M | 42,843M | 32,894M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 1,473.11M | 1,626.28M | 1,838.58M | 2,029.56M | 2,110.34M |
| Gross Profit | 916.28M | 959.60M | 1,069.03M | 1,169.49M | 1,209.84M |
| Operating income | 318.55M | 303.96M | 307.52M | 348.60M | 371.90M |
| Income before tax | 326.45M | 661.78M | 277.54M | 354.23M | 388.81M |
| Net income | 218.75M | 444.46M | 200.54M | 318.02M | 288.13M |
| EBITDA | 381.88M | 381.73M | 398.78M | 446.91M | 470.81M |
| Diluted EPS | 0.52 | 1.06 | 0.48 | 0.77 | 0.70 |
| Dividends Per Share | 0.20 | 0.20 | 0.24 | 0.23 | 0.23 |
| Total Assets | 2,536.58M | 3,162.05M | 3,220.90M | 3,652.68M | 3,534.22M |
| Total liabilities | 770.65M | 848.70M | 924.14M | 948.79M | 890.94M |
| Total equity | 1,765.92M | 2,313.35M | 2,289.41M | 2,687.56M | 2,628.17M |
| Operating cash flow | 231.08M | 187.57M | 100.13M | 386.55M | 296.62M |
Valuation Measures
| Mar 2019 | |
| PER | 20.96 |
| ROA | 8.19% |
| ROE | 11.08% |
| Operating margin | 17.62% |
| Profit margin | 13.65% |
Key executives
- Chairman & Chief Executive Officer: Akira Kurokawa
- President, COO & Representative Director: Shigeo Taniuchi
- CFO, General Manager-Finance & Administration: Kazuo Koshiji
- Chief Information Officer & Executive Officer: Noriaki Yamamoto
- Chief Scientific Officer, General Manager-R&D: Naveed K. Shams
Shareholders
- MFS International (UK) Ltd. (5.3%)
- Black Creek Investment Management, Inc. (5.0%)
- Massachusetts Financial Services Co. (4.2%)
- Mitsubishi UFJ Financial Group, Inc. (3.4%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.2%)
- Nippon Life Insurance Co. (2.6%)
- Nomura Asset Management Co., Ltd. (2.5%)
- The Vanguard Group, Inc. (2.5%)
- Ono Pharmaceutical Co., Ltd. (2.3%)
- Nikko Asset Management Co., Ltd. (2.0%)
Contact Details
- Website:http://www.santen.co.jp
- Address: Grand Front Osaka Tower A, 25/F, 4-20 Ofuka-cho, Osaka, 530-8552, Japan
- Phone: +81.6.6321.7000
Related Companies
- Santen Pharmaceutical Restricted Stock Compensation Plan
- Santen Philippines, Inc.
- Santen Pharma Malaysia Sdn. Bhd.
- Santen Thailand Co. Ltd.
- Santen SA
- Santen Eye Care Co., Ltd.
- Santen Business Services Co., Ltd.
- Claire Co., Ltd.
- Santen Italy SRL
- Santen Pharmaceutical Spain SL
- SantenPharma AB
- Santen India Pvt Ltd.
- Santen Pharmaceutical Korea Co., Ltd.
- Santen Pharmaceutical Asia Pte Ltd.
- Santen Pharmaceutical Sales & Marketing (Suzhou) Co., Ltd.
- Taiwan Santen Pharmaceutical Co., Ltd.
- Santen SAS
- Santen Pharmaceutical Trust
- Santen Pharmaceutical (China) Co., Ltd.
- Santen Holdings U.S., Inc.
- Santen Pharmaceutical Pension Fund
- Santen GmbH
- Santen Oy
- Santen Holdings EU BV
- InnFocus, Inc.
- Santen, Inc.
- Star Ab Oy
- Advanced Vision Science, Inc.
Competitors
- Nicox SA
- EyePoint Pharmaceuticals, Inc.
- Healios KK
- G-treeBNT Co., Ltd.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 1 Apr, 2020